دورية أكاديمية
Evaluation of Pain and Use of Analgesics during Medical Termination of Pregnancy in Real-Life Settings
| العنوان: | Evaluation of Pain and Use of Analgesics during Medical Termination of Pregnancy in Real-Life Settings |
|---|---|
| المؤلفون: | Aubert Agostini, Laura Miquel, Hélène Herman-Demars, Sandrine Frantz, Marie Sicot, for RYMMA investigator group |
| المصدر: | Pain and Therapy, Vol 12, Iss 2, Pp 563-574 (2023) |
| بيانات النشر: | Adis, Springer Healthcare, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Anesthesiology |
| مصطلحات موضوعية: | Mifepristone, Misoprostol, Medical termination of pregnancy, Pain management, Anesthesiology, RD78.3-87.3 |
| الوصف: | Abstract Introduction Women frequently report pain associated with medical termination of pregnancy (MToP), and its management can differ largely between centres. This study aimed at evaluating in real-life settings pain related to MToP and its management in France. Methods This was a non-interventional prospective, longitudinal study run in 23 centres between 2015 and 2016 that included 893 pregnant women. Pain was reported by women prior any curative analgesic intake (CAI) through a five-level Likert scale (absence, mild, moderated, severe, extreme). Modalities of analgesic prophylaxis prescription (APP) and intake (API) and CAI were collected. Risk factors were investigated using ordinal logistic regression (for pain) or logistic regression (for CAI) with stepwise selection of variables. Results APP was prescribed to 657 (73.7%) women irrespective of the gestational age, among whom 386 (73.7%) took the treatment. Out of 740 women who documented their pain symptoms prior to any CAI, few declared no pain (n = 94, 12.7%) or intense pain (n = 88, 11.9%). The majority reported mild or moderate pain (n = 558, 75.4%). On multivariate analysis adjusted on gestational age, increasing initial [odds ratio (OR) 1.25, 95% confidence interval (CI) 1.06–1.47] or total dose (OR 1.15, 95% CI 1.05–1.26) of misoprostol taken were independent factors associated with risk of more pain. When adjusting for gestational age, initial dose of misoprostol (OR 1.69, 95% CI 1.45–2.66) and pain experienced (OR 3.58, 95% CI 2.82–4.55) were significantly associated with higher risk of CAI while API (OR 0.52, 95% CI 0.36; 0.75) was negatively associated. Conclusions Most of the women received an APP, but not all used it. API and gestational age were not related to different risks of more pain following MToP, whereas history of at least one child showed a negative association. Higher doses of misoprostol were strongly associated with both pain and CAI. API was associated with a decreased risk of CAI. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2193-8237 2193-651X |
| Relation: | https://doaj.org/toc/2193-8237; https://doaj.org/toc/2193-651X |
| DOI: | 10.1007/s40122-023-00477-2 |
| URL الوصول: | https://doaj.org/article/ed6ed7451ed14d12bec4bd1fe75ba0a8 |
| رقم الأكسشن: | edsdoj.6ed7451ed14d12bec4bd1fe75ba0a8 |
| قاعدة البيانات: | Directory of Open Access Journals |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 21938237 2193651X |
|---|---|
| DOI: | 10.1007/s40122-023-00477-2 |